The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: Pathophysiology and pharmacotherapy of overactive bladder

Journal of Pharmacological Sciences

Volumn 112, Issue 2, 2010, Pages 128-134

  Yoshida, Masaki ^a   Masunaga, Koichi ^b   Nagata, Takashi ^c   Yono, Makoto ^d   Homma, Yukio ^e  

^a NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

^b Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology   (Japan)

^c Toshiba Hospital   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antimuscarinic drug; Lower urinary tract; Muscarinic receptor; Overactive bladder; Pathophysiology; Pharmacotherapy

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; APREPITANT; BOTULINUM TOXIN A; CAPSAICIN; DARIFENACIN; DESMOPRESSIN; METHOCTRAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NIFEDIPINE; NITRIC OXIDE; OXYBUTYNIN; PIRENZEPINE; PROPIVERINE; PROSTAGLANDIN; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

AUTONOMIC NERVOUS SYSTEM; BLADDER NECK STENOSIS; BLURRED VISION; CONSTIPATION; DETRUSOR MUSCLE; HUMAN; LOWER URINARY TRACT SYMPTOM; NAUSEA; NEUROTRANSMISSION; NOCTURIA; OVERACTIVE BLADDER; SHORT SURVEY; TACHYCARDIA; URINE RETENTION; UROTHELIUM; VOMITING; XEROSTOMIA;

EID: 77249155715     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R12FM     Document Type: Short Survey

References (51)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardization of terminology of lower urinary tract function: report from the standadisation sub-committee of international continence society. Neurourol Urodyn. 2002;21: 167-178.
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760-766.
3. Stewart WF, Van Rooyen JB, Cundiff GW, Abram P, Herzog A, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
4. Homma Y, Kakizaki H, Gotoh M, Takei M, Yamanishi T, Hayashi K. The Members of Committee. [Epidemiologic survey on lower urinary tract symptoms in Japan.] J Neurogenic Bladder Soc. 2003;14:266-277. (in Japanese)
5. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50: 1306-1315.
6. Speakman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosling JA. Bladder outflow obstruction - a cause of denervation supersensitivity. J Urol. 1987;138:1461-1466.
7. Boselli C, Govoni S, Condino AM, D'Agostino G. Bladder instability: a re-appraisal of classical experimental approaches and development of new therapeutic strategies. J Auton Pharmacol. 2001;21:219-229.
8. O'Reilly BA, Kosaka AH, Chang TK, Ford AO, Popert R, McMahon SB. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int. 2001;87:617-622.
9. Christ GJ, Day NS, Day M, Zhao W, Persson K, Pandita RK, et al. Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1241-R1248.
10. Haferkamp A, Mundhenk J, Bastian PJ, Reitz A, Dorsam J, Pannek J, et al. Increased expression of connexin 43 in the overactive neurogenic detrusor. Eur Urol. 2004;46:799-805.
11. Downie JW, Armour JA. Mechanoreceptor afferent activity 133 OAB Pathophysiology and Pharmacotherapy compared with receptor field dimensions and pressure changes in feline urinary bladder. Can J Physiol Pharmacol. 1992;70: 1457-1467.
12. Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA. Localized contractions in the normal human bladder and in urinary urgency. BJU Int. 2005;95:1002-1005.
13. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84: 935-986.
14. Yoshimura N, Chancellor MB. Physiology and pharmacology of the bladder and urethra. In: Wein AJ, editor. Campbell-Walsh urology. Vol. 3, 9th ed, Section XIV, Chapter 56. Philadelphia, PA: Saunders; 2007. p. 1922-1972.
15. Kubota Y, Kojima Y, Hayase M, Hirose M, Okada O, Sasaki S, et al. Association between bladder overactivity and increased numbers of interstitial cells in the guinea pigs with partial bladder outlet obstruction. J Urol. 2007;177 4 Suppl:85 (abstract).
16. Biers SM, Reynard JM, Doore T, Brading AF. The functional effects of a c-kit tyrosine inhibitor on guinea-pig and human detrusor. BJU Int. 2006;97:612-616.
17. Kubota Y, Biers SM, Kohri K, Brading AF. Effects of imatinib mesylate (Glivec) as a c-kit tyrosine kinase inhibitor in the guinea-pig urinary bladder. Neurourol Urodyn. 2006;25:205-210.
18. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786-799.
19. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol. 2002;168: 1897-1913.
20. Araki I, Du S, Kamiyama M, Mikami Y, Matsushita K, Komuro M, et al. Overexpression of epithelial sodium channels in epithelium of human urinary bladder with outlet obstruction. Urology. 2004;64:1255-1260.
21. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int. 2004;45:987-993.
22. Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, et al. Non-neuronal cholinergic system in human bladder urothelium. Urology. 2006;67:425-430.
23. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006;175:1773-1776.
24. Kim DK, Thomas CA, Smith C, Chancellor MB. The case for bladder botulinum toxin application. Urol Clin North Am. 2006; 33:503-510.
25. Hawthorn MH. Chapple CR. Cock M. Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129:416-419.
26. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtype in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in aging. Br J Pharmacol. 2005;144:1089-1099.
27. Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, et al. Localization of M 2 and M 3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006;176:367-373.
28. Yoshida M, Masunaga K, Nagata T, Maeda Y, Miyamoto Y, Kudoh J, et al. Attenuation of non-neuronal ATP release from human bladder mucosa by muscarinic agents. LUTS. 2009;2: 88-92.
29. de Groat WC, Downie JW, Levin RM, Long Lin AT, Morrison JFB, Nishizawa O, et al. Basic neurophysiology and neuropharmacology. In Abrams P, Khoury S, Wein A, editors. In: Incontinence, 1st International Consultation on Incontinence. Plymouth: Plymbridge Distributors Ltd.; 1999. p. 105-154.
30. Andersson K-E, Chapple CR, Cardozo L, Cruz H, Hashim H, Michel MC, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, 4th International Consultation on Incontinence. Plymouth: Health Publication Ltd.; 2009. p. 631-699.
31. Chapple C, Khullar V, Gabriel Z, Doolry JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48:5-26.
32. Chapple CR, Patroneva A, Raines SR. Effect of an ATP sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol. 2006;49:879-886.
33. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:77-85.
34. Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol. 2006;176:2535-2540.
35. Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26:752-756.
36. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84: 935-986.
37. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147 Suppl 2:S88-S119.
38. Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:473-481.
39. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170:649-653.
40. Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999;16:680-685.
41. Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999;126:819-825.
42. Igawa Y, Yamazaki Y, Takeda H, Kaidoh K, Akahane M, Ajisawa Y, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol. 2001;165:240-244.
43. Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, et al. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther. 1999;288:1367-1373.
44. Morita T, Iizuka H, Iwata T, Kondo S. Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J Smooth Muscle Res. 2000;36:21-32.
45. Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98:1310-1314.
46. Badawi JK, Seja T, Uecelehan H, Honeck P, Kwon ST, Bross S, et al. Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology. 2007;69:785-790.
47. Leon LA, Hoffman BE, Gardner SD, Laping NJ, Evans C, Lashinger ES, et al. Effects of the beta3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2- (3-chlorophenyl)-2-hydroxyethyl] amino]propyl]-1,3-benzodioxole-2,2- dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008;326:178-185.
48. Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs. 2007;16:999-1007.
49. Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn. 2007;26 6 Suppl:920-927.
50. Patel AK, Patterson JM, Chapple CR. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol. 2006;50:684-710.
51. Andersson K-E, Gratzke C. Bladder pharmacology and treatment of lower urinary tract: recent advances. UroToday Int J. 2008 Aug;1(2). doi:10.3834/uij.1939-4810.2008.07.06